Clinical Trials

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT04487080 2026-04-22

MARIPOSA

1,074 enrolled 13 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-04-22

MARIPOSA-2

776 enrolled 13 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT01682083 2026-04-21

COMBI-AD

870 enrolled 15 charts 1 FDA

Dermatologic

Melanoma, Neoplasms

NCT02296125 2026-04-21

FLAURA

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT03710876 2026-04-21

INFINITE

Other solid neoplasmThoracic

53 enrolled 23 charts

Mesothelioma, Malignant

NCT03914612 2026-04-21

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04765059 2026-04-21

COMPEL

98 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT04083235 2026-04-20

NAPOLI 3

770 enrolled 13 charts 2 FDA

Metastatic Adenocarcinoma of the Pancreas

NCT01298323 2026-04-17

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

205 enrolled 10 charts

Neoplasm Metastasis, Carcinoma, Medullary

NCT03653507 2026-04-17

GLOW

507 enrolled 65 charts 2 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04076059 2026-04-17

China ARCHES

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

NCT05587296 2026-04-16

OASIS-4

474 enrolled 14 charts

Hot Flashes

NCT04924062 2026-04-15

KEYNOTE-966

158 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT02912559 2026-04-14

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

712 enrolled 14 charts

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT00217737 2026-04-13

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

2,431 enrolled 13 charts

Colonic Neoplasms

NCT00310180 2026-04-13

TAILORx

10,273 enrolled 14 charts

Breast

Breast Neoplasms

NCT00569127 2026-04-13

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

427 enrolled 17 charts

EndocrineNET

Neuroendocrine Tumors

NCT00843882 2026-04-13

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Classical hematologyMyeloidOther hematologic neoplasm

247 enrolled 19 charts

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01167712 2026-04-13

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

692 enrolled 11 charts

Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms

NCT01272037 2026-04-13

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

5,018 enrolled 14 charts

Breast

Carcinoma, Intraductal, Noninfiltrating

NCT01575548 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

129 enrolled 11 charts

Carcinoma, Renal Cell

NCT01886872 2026-04-13

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

547 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01946204 2026-04-13

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT02306161 2026-04-13

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

312 enrolled 14 charts

Sarcoma

Sarcoma, Ewing

NCT02466971 2026-04-13

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

450 enrolled 11 charts

Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT02489318 2026-04-13

TITAN

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT02506153 2026-04-13

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

1,301 enrolled 16 charts

Dermatologic

Melanoma

NCT02567435 2026-04-13

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

325 enrolled 14 charts

Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT03055013 2026-04-13

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

819 enrolled 12 charts

Carcinoma, Renal Cell

NCT03301220 2026-04-13

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 2 FDA

Plasma cell

Smoldering Multiple Myeloma

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 2 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03390504 2026-04-13

THOR

629 enrolled 32 charts

Urothelial Cancer

NCT03462719 2026-04-13

GLOW

LymphoidOther hematologic neoplasm

211 enrolled 23 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03737981 2026-04-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

465 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03748641 2026-04-13

MAGNITUDE

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT03811002 2026-04-13

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

544 enrolled 29 charts

Lung Neoplasms

NCT03901963 2026-04-13

AURIGA

200 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts 3 FDA

Lymphoid

Hodgkin Disease

NCT03957590 2026-04-13

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

370 enrolled 17 charts

Esophageal Squamous Cell Carcinoma

NCT04181827 2026-04-13

CARTITUDE-4

419 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 2 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04538664 2026-04-13

PAPILLON

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04650581 2026-04-13

FINER

250 enrolled 13 charts

Breast

Breast Neoplasms

NCT04936308 2026-04-13

SOLSTICE

453 enrolled 25 charts

Arthritis, Psoriatic

NCT05388669 2026-04-13

PALOMA-3

418 enrolled 16 charts